Sanofi receives FDA approval of once-daily basal insulin Toujeo®
26 February 2015 | By Sanofi
The U.S. Food and Drug Administration (FDA) has approved Sanofi's Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes...